"The results of the lubiprostone trial are very encouraging for Japanese patients suffering from this condition, and the product will be a major breakthrough in improving the quality of life for CIC patients," said Gary M. Winer, President, Abbott Japan, which holds commercialization rights to lubiprostone in Japan.

Sucampo is developing lubiprostone in Japan as a potential treatment for patients with chronic idiopathic constipation (CIC). In February 2009, Sucampo entered into a license, commercialization and supply agreement for lubiprostone with Abbott Japan Co. Ltd. under which Abbott received exclusive rights to commercialize lubiprostone in Japan for the treatment of CIC and the right of first refusal to any additional indications for which lubiprostone is developed in Japan. Sucampo continues to lead the development of and regulatory activity for lubiprostone in Japan.

SOURCE Sucampo Pharmaceuticals, Inc.,